The White House on Friday said Novo Nordisk’s weight-loss drugs Wegovy and Ozempic were among the 15 medications picked for a ...
Mounjaro, like other GLP-1 drugs, carries potential side effects, including nausea, vomiting, dehydration, and hypoglycaemia ...
Federal officials are targeting the blockbuster drugs as part of their ongoing initiative to lower drug costs.
Tripling the dosage of the Wegovy weight-loss drug leads to more weight loss, Novo Nordisk said Friday.
The Centers for Medicare and Medicaid Services (CMS) on Friday announced 15 additional Medicare Part D drugs selected for the ...
The late-stage trial of semaglutide, which it markets as Wegovy to treat obesity, showed that those who took a dose of 7.2 milligrams lost an average of 20.7% of their weight over 72 weeks. A third of ...